jzp926
jzp926: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Jazz Pharmaceuticals plc (JAZZ)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | Phase 2/Phase 3 |
Clinical Trials (1)
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy
Frequently asked questions
Who is developing jzp926?
jzp926 is being developed by Jazz Pharmaceuticals plc.
How many clinical trials involve jzp926?
BioSniper tracks 1 clinical trial involving jzp926.
Analyze Jazz Pharmaceuticals plc & jzp926 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company